Navigation Links
Novus Scientific Announces the World's 1st Long-Term Absorbable Mesh as an Alternative to Non-Absorbable Synthetic Mesh
Date:9/26/2011

SINGAPORE, Sept. 26, 2011 /PRNewswire/ -- Novus Scientific today announced TIGR® Matrix Surgical Mesh, the world's first and only long-term resorbable mesh, as an alternative to permanent synthetic mesh. First introduced in the US in 2010, TIGR® Matrix Surgical Mesh is currently being used in many surgical applications as an alternative to permanent synthetic mesh and expensive biologic devices.

Characteristics of TIGR® Matrix Surgical Mesh
TIGR® Matrix Surgical Mesh is knitted from two different synthetic absorbable fibers, possessing different degradation characteristics. The first fiber, making up approximately 40% of the matrix by weight, is a copolymer of glycolide, lactide, and trimethylene carbonate. The second fiber, making up approximately 60% of the matrix by weight, is a copolymer of lactide, and trimethylene carbonate. Both fibers degrade by bulk hydrolysis once implanted.

Based on the product's absorption characteristics, in vitro testing showed that the first fiber retains its functional capabilities for 1-2 weeks and in vivo studies in the abdominal wall of sheep showed that the first fiber was fully absorbed after 4 months. The same in vitro testing showed that the second fiber retains its functional capabilities for 6 months and in vivo studies in the abdominal wall of sheep indicated that the second fiber is completely absorbed after approximately 36 months.

"We at Novus Scientific have long prided ourselves on identifying clinical need and developing innovative products to address that need. We are pleased to highlight the fact that TIGR® Matrix Surgical Mesh is a viable alternative to permanent synthetic mesh on both a physiological treatment level and a budgetary level when used by physicians performing surgeries that reinforce soft tissue where weakness exists," said Thomas Engstrom, Founder and CEO of Novus Scientific.

"Surgeons want to provide the best treatment for their patients. Now, TIGR® Matrix Surgical Mesh offers surgeons an alternative to non-absorbable synthetic mesh," commented James Archetto, President of Novus Scientific, Inc.

Mark Swierzewski, MD, a urological surgeon from Tampa, FL stated, "TIGR® Matrix has been a part of my practice since 2010. It provides me and my patients with a viable alternative to non-absorbable synthetic mesh."

About Novus Scientific
Novus Scientific (www.novusscientific.com) is an innovator in the development and commercialization of absorbable synthetic medical devices. Visit our PRESSROOM: http://www.mynewsdesk.com/pressroom/novus-scientific

TIGR® is a trademark of Novus Scientific Pte. Ltd

CONTACT:
jim.archetto@novusscientific.com
781-577-2599


'/>"/>
SOURCE Novus Scientific
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Novus Scientific Receives FDA Clearance for TIGR(TM) Matrix Surgical Mesh - Worlds 1st Long-Term Resorbable Synthetic Mesh
2. Novus Scientific Announces the Sales Launch for TIGRâ„¢ Matrix Surgical Mesh - Worlds 1st Long-Term Resorbable Synthetic Mesh
3. Novus Scientific and Singapore Association of Plastic Surgeons (SAPS) Host the Inaugural Event of SOFTISSUE - The Issue of Soft Tissue, Featuring James J. Chao, M.D., FACS, Professor of Plastic Surgery and Orthopedic Surgery, University of Califor
4. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
5. Avicena Scientific Collaborator Advances Program for Using Energy Enhancing Molecules to Treat Neuromuscular Diseases
6. Boston Scientific Announces Schedule for European Society of Cardiology Congress 2007
7. Boston Scientific to Release Broad Range of Clinical Trial Data Reinforcing Safety and Efficacy of Taxus(R) Coronary Stent Systems at TCT 2007
8. Preliminary Results of Randomized Pilot Study Show Comparable Efficacy for OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) and Boston Scientifics Taxus(R) Stent in Patients at High Risk of Restenosis
9. Boston Scientific PROMUS(TM) and TAXUS(R) Stents Continue Strong Performance in Safety and Efficacy Measures
10. Boston Scientifics Next-Generation Stent Shows Improved Clinical Outcomes in Complex Lesions
11. Positive Five-Year Safety Data for TAXUS(R) Stent Reported in Boston Scientific Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... 2017 Research and Markets has announced ... & Forecast By Type (Insource IONM, Outsource IONM), By Region ... their offering. ... The global Intraoperative Neuromonitoring (IONM) market is expected ... market is anticipated to witness significant growth in the forecast ...
(Date:3/29/2017)... Research and Markets has announced the addition ... their offering. ... The global gas chromatograph market to grow at a CAGR of ... Gas Chromatograph Market 2017-2021, has been prepared based on an in-depth ... market landscape and its growth prospects over the coming years. The ...
(Date:3/29/2017)... HANOVER, N.J. , March 29, 2017 /PRNewswire/ ... Drug Administration (FDA) has accepted the company,s Biologics ... for CTL019 (tisagenlecleucel-T), an investigational chimeric antigen receptor ... (r/r) pediatric and young adult patients with B-cell ... BLA submission by Novartis for a CAR-T. The ...
Breaking Medicine Technology:
(Date:3/29/2017)... (PRWEB) , ... March 29, 2017 , ... In the ... to 300,000 people each year develop other types of metastatic brain tumors(3). Though most ... the brain(3). As efforts focus on finding more effective treatment options, the San ...
(Date:3/29/2017)... Massachusetts (PRWEB) , ... March 30, 2017 , ... Youth ... had great success and feedback from high school and college students who have participated ... being held July 7-23 and YFI is now accepting applications for enrollment. Visit ...
(Date:3/29/2017)... , ... March 29, 2017 , ... ... with or without a referral to new patients from Burnaby, BC. Patients in ... other full mouth reconstruction services, can see the esteemed team at Wall Centre ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... and other outpatient facilities, and who are the most active developers? , ... Revista and Healthcare Real Estate Insights (HREI) found that outpatient medical real estate ...
(Date:3/29/2017)... ... March 29, 2017 , ... The assembly of synthetic DNA ... many repetitive steps and often scientists require many different versions of DNA. Therefore, ... results in a lower error rate and cost saving for reagents and consumables. ...
Breaking Medicine News(10 mins):